Funds Holding Merrimack Pharmaceuticals Inc

 
Fund Quotes for Funds Holding Merrimack Pharmaceuticals Inc top ^
  • Holdings: Bank of America Corporation , Apple Inc , American International Group Inc , Genworth Financial Inc , Merrimack Pharmaceuticals Inc ,
  • Category: Large Growth
  • Morningstar Rating: 3 Stars
Sign-up for brblx investment picks

 
Stock Quotes for Merrimack Pharmaceuticals Inc top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Distressed
Sign-up for mack investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Distressed
Sign-up for mack investment picks

 
News Articles for Merrimack Pharmaceuticals Inc top ^
Baxter International Inc. (NYSE:BAX) and Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today jointly announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.'' Through the agreement, Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the United States and Taiwan, and Merrimack retains commercialization rights in the United States; the rights in Taiwan are held separately.
Sign-up for Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 investment picks
Data Presented as Part of Meta-Analysis Showing MM-121's Favorable Impact on Progression Free Survival in 38-54 Percent of Patients With Ovarian, Lung and Breast Cancers Across Three Phase 2 Studies MADRID, Spain, Sept.
Sign-up for Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer investment picks
CAMBRIDGE, Mass., Nov.
Sign-up for Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call investment picks
CAMBRIDGE, Mass., Nov.
Sign-up for Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results investment picks
Clinical data from Phase 1 studies of MM-398 and MM-151 presented BARCELONA, Spain, Nov.
Sign-up for Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Funds Holding Merrimack Pharmaceuticals Inc
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Funds Holding Merrimack  |  Next: Funds Holding Mesa Laboratories, Inc.